The case for Meso's CLBP, page-4

Thanks for posting. Appreciate it a lot. The author of the article you refer to may not be aware of MSB's product but I've seen it discussed online; they've looked up phase 3 trials and like the idea of a treatment that 'works with the body.'

I think the problem with the MaBs drugs is the publicity surrounding Actemra deaths. These things seem to be getting more dangerous. 'Wonder drug' Canakinumab for CHF is also one I believe. FDA stopped clinical trial fof gouty arthritis as it was too dangerous for anything non life-threatening. Public Citizen said just a single dose raised the risk of serious infections.